Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/16/2913698/0/en/Recce-Pharmaceuticals-Receives-2-Million-Grant-from-U-S-Department-of-Defense-for-RECCE-327-Gel.html
https://www.globenewswire.com/news-release/2024/07/10/2911044/0/en/Recce-Pharmaceuticals-Announces-Positive-Preclinical-Efficacy-Data-Against-WHO-Priority-Pathogen-Acinetobacter-baumannii.html
https://www.globenewswire.com/news-release/2024/07/01/2906635/0/en/Recce-Pharmaceuticals-Reports-Positive-Data-from-Phase-I-II-Urinary-Tract-Infection-UTI-Urosepsis-Rapid-Infusion-Trial-of-RECCE-327.html
https://www.globenewswire.com/news-release/2024/06/25/2903735/0/en/Recce-Pharmaceuticals-Receives-Ethics-Approval-to-Broaden-RECCE-327-Gel-Trials-Across-all-Topical-Bacterial-Skin-Infections.html
https://www.globenewswire.com/news-release/2024/06/20/2901619/0/en/Recce-Pharmaceuticals-Announces-Addition-of-RECCE-327-to-The-World-Health-Organization-s-List-of-Antibacterial-Products-in-Clinical-Development.html
https://www.globenewswire.com/news-release/2024/06/12/2897492/0/en/Recce-Pharmaceuticals-Completes-Dosing-Additional-Cohort-in-Phase-I-II-UTI-Urosepsis-Rapid-Infusion-Trial.html
https://www.globenewswire.com/news-release/2024/05/17/2884179/0/en/Recce-Pharmaceuticals-Doses-First-Participants-in-Next-Cohort-of-Phase-I-II-Urinary-Tract-Infections-and-Urosepsis-Rapid-Infusion-Clinical-Trial.html
https://www.globenewswire.com/news-release/2024/05/13/2880360/0/en/Recce-Pharmaceuticals-Reports-Positive-Preclinical-Data-of-RECCE-327-in-Lung-Infection-Pilot-Study.html
https://www.globenewswire.com/news-release/2024/05/08/2877749/0/en/Recce-Pharmaceuticals-Granted-New-Patent-in-China-for-RECCE-Anti-Infectives.html